Tokyo-based late-stage clinical biotech developing KORTUC, an injectable hydrogen-peroxide-based radiosensitizer that reduces tumor hypoxia and increases the effectiveness of cancer radiotherapy
Tokyo-based late-stage clinical biotech developing KORTUC, an injectable hydrogen-peroxide-based radiosensitizer that reduces tumor hypoxia and increases the effectiveness of cancer radiotherapy. The company is conducting pivotal Phase II trials, initially for locally advanced breast cancer, and is exploring use across solid tumors and to enhance antitumor immune responses, including potential improvement of immune checkpoint inhibitor efficacy.